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Abstract 
Burst-firing in thalamic neurons is known to play a key role in mediating thalamocortical (TC) 
oscillations that are associated with non-REM sleep and some types of epileptic seizure. Within 
the TC system the primary output of GABAergic neurons in the reticular thalamic nucleus 
(RTN) is thought to induce the de-inactivation of T-type calcium channels in thalamic relay (TR) 
neurons, promoting burst-firing drive to the cortex and the propagation of TC network activity. 
However, RTN neurons also project back onto other neurons within the RTN. The role of this 
putative negative feedback upon the RTN itself is less well understood, although is hypothesized 
to induce de-synchronization of RTN neuron firing leading to the suppression of TC oscillations. 
Here we tested two hypotheses concerning possible mechanisms underlying TC oscillation 
modulation. Firstly, we assessed the burst-firing behavior of RTN neurons in response to 
GABAB receptor activation using acute brain slices. The selective GABAB receptor agonist 
baclofen was found to induce suppression of burst-firing concurrent with effects on membrane 
input resistance. Secondly, RTN neurons express CaV3.2 and CaV3.3 T-type calcium channel 
isoforms known contribute towards TC burst-firing and we examined the modulation of these 
channels by GABAB receptor activation.  Utilizing exogenously expressed T-type channels we 
assessed whether GABAB receptor activation could directly alter T-type calcium channel 
properties. Overall, GABAB receptor activation had only modest effects on CaV3.2 and CaV3.3 
isoforms. The only effect that could be predicted to suppress burst-firing was a hyperpolarized 
shift in the voltage-dependence of inactivation, potentially causing lower channel availability at 
membrane potentials critical for burst-firing. Conversely, other effects observed such as a 
hyperpolarized shift in the voltage-dependence of activation of both CaV3.2 and CaV3.3 as well 
as increased time constant of activation of the CaV3.3 isoform would be expected to enhance 
burst-firing. Together, we hypothesize that GABAB receptor activation mediates multiple 
downstream effectors that combined act to suppress burst-firing within the RTN. It appears 
unlikely that direct modulation of T-type calcium channels is major contributor to this 
suppression. 
 
Introduction 
Thalamocortical (TC) oscillations play important roles in determining sleep and awake states, as 
well as contributing to  the initiation and/or propagation of some types of epileptic seizure 
(Huguenard, 1999; Beierlein et al., 2002; Contreras, 2006). The relevant TC network is 
comprised of reticular thalamic nucleus (RTN) neurons, thalamic relay (TR) neurons and cortical 
layer V/VI neurons. While TR and cortical neurons send glutamatergic projections both to each 
other and to the RTN, the GABAergic RTN neurons project to TC neurons and also feedback to 
other neurons within the RTN. The GABAergic RTN innervation is believed to hyperpolarize 
TR neurons, driving the de-inactivation of low threshold T-type calcium channels which then 
promotes burst-firing either upon subsequent cessation of hyperpolarization (rebound burst-
firing) or as a result of depolarizing drive from the cortex (Contreras, 2006). This burst-firing is 
believed to occur during drowsiness and non-REM sleep as well as in some types of epileptic 
seizure, such as absence seizures (Cain and Snutch, 2012a).  Alternatively, in the absence of 
hyperpolarization from the RTN TR neurons display a tonic firing pattern, believed to associate 
with the relay of sensory information during the awake state (Sherman, 2001).  
T-type calcium channels (CaV3.1, CaV3.2 and CaV3.3) underlie a low-threshold spike or calcium 
potential (LTCP),  that activates around -60 mV, peaks at ~ -40 mV and is 50 to 150 ms in 
duration (Huguenard and Prince, 1992; Cain and Snutch, 2010, 2012b). It is this LTCP that 
triggers high frequency action potential firing to produce bursting (Kozlov et al., 1999; Chemin 
et al., 2002; Chorev et al., 2006; Cain and Snutch, 2010). In RTN neurons mRNA expression 
analysis has identified the CaV3.2 and CaV3.3 T-type isoforms (Talley et al., 1999) with the 
relative contribution ratio estimated to be approximately 35:65 (CaV3.2:CaV3.3) as determined 
by pharmacological sensitivity (Joksovic et al., 2005, 2006, 2007) and selective knockout in 
mice (Astori et al., 2011). Of note, attenuation of the LTCP with high affinity T-type calcium 
channel antagonists both prevents RTN burst-firing in acute brain slices and prevents absence 
seizures in vivo (Tringham et al., 2012). Relevant to the underlying mechanism of epileptic 
activity, burst-firing in RTN neurons occurs in a time-locked manner with spike-wave discharges 
in both the GAERS and WAG/Rij rodent models of absence epilepsy and is thought to play a 
significant role in synchronization of the thalamocortical circuitry (Inoue et al., 1993; Pinault et 
al., 1998; Pinault, 2004; Cain and Snutch, 2012b). Evidence suggests that burst-firing of RTN 
neurons promotes synchrony of intra-RTN, thalamic and thalamocortical rhythms via the 
intrinsic tendency of burst-firing to synchronize neuronal activity. Conversely, tonic firing is 
thought to lead to de-synchrony within the RTN, which would be expected to suppress 
thalamocortical oscillations (Thomas and Lytton, 1998).  
Gamma-aminobutyric acid B (GABAB) receptors are metabotropic G protein-coupled receptors 
that couple to Gi/G0 to mediate slow inhibitory neurotransmission, typically via activation of 
potassium channels (Padgett and Slesinger, 2010; Pinard et al., 2010). These heterodimeric 
receptors have been implicated in a number of CNS disorders, for example, anxiety, depression 
and epilepsy and as such, have been proposed as promising therapeutic targets (Kim et al., 2001; 
Tadavarty et al., 2011; Benke, 2013; Kumar et al., 2013). The inhibition of GABAB receptors has 
been shown to induce seizure-like activity in thalamic slices and it has been proposed that intra-
RTN inhibition reduces the number of RTN bursts (Destexhe et al., 1996; Destexhe, 1998; Sohal 
and Huguenard, 2003). The GABAB receptor agonist baclofen activates an outward conductance 
in RTN neurons (Ulrich and Huguenard, 1996) which is believed to provide a sufficient time 
constant of hyperpolarization to allow for both the synchronization of burst-firing of RTN 
neurons and promote intrathalamic spindle oscillations (Wang and Rinzel, 1993; Golomb et al., 
1994). Given the feedback circuitry within the RTN it remains to be determined however, 
whether there are any effects of intra-RTN GABAB receptor activation on RTN ionic 
conductances and burst-firing.  
Here we report that GABAB receptor activation inhibits RTN burst-firing in acute rat thalamic 
brain slices. This coincides with hyperpolarization of the neuronal resting membrane potential 
and decreased input resistance, both of which likely contribute towards the suppression of burst-
firing. We further examine the effects of the direct modulation of T-type calcium channels by co-
expression with heterodimeric GABAB1b and GABAB2 receptors.  GABAB receptor activation is 
found to significantly shift the voltage-dependence of inactivation of both the CaV3.2 and CaV3.3 
T-type isoforms which are hypothesized to contribute to the suppression of burst-firing in RTN 
neurons. However, additional effects such as a hyperpolarized shift in the voltage dependence of 
activation of both CaV3.2 and CaV3.3 as well as an increase in the activation kinetics of the 
CaV3.3 isoform would be predicted to increase functional T-type currents and therefore increase 
burst-firing. 
 
Results 
Baclofen suppresses burst-firing in the RTN 
In order to examine burst-firing activity and passive membrane properties current clamp 
recordings were performed in acute thalamic brain slices using 1000 ms hyperpolarizing and 
depolarizing current injections from their intrinsic resting membrane potential. RTN neurons 
responded to depolarizing current injection with burst-firing, often followed by tonic firing upon 
further depolarization (Figure 1a).  In contrast, current injection causing hyperpolarization did 
not induce rebound burst-firing (Figure 1a). Application of baclofen (50 µM) significantly 
increased the depolarizing current injection required to induce burst-firing (control = 63.3 ± 
12.02 pA, baclofen= 145.6 ± 18.0 pA (n=8); p<0.005) (Figures 1a and 1b). Application of 
baclofen to cells pre-treated with the GABAB receptor antagonist CGP35348 (control + CGP = 
82.9 ± 14.8 pA, baclofen + CGP = 118.3 ± 21.2 pA (n=9)) or H20 control (control = 71.7 ± 11.4, 
H2O = 83.3 ± 14.8 (n=6)) did not significantly affect the current threshold for burst-firing 
(Figure 1b). Comparing the percentage increase in current for the three treatment groups using 
multiple comparisons confirmed a significant increase in the current injection required to induce 
burst-firing in the baclofen versus CGP35348 pre-treated and H2O control application groups 
(Figure 1c; baclofen = 169.6 ± 30.7%, baclofen + CGP = 50.7 ±7.2%, H2O = 16.8 ± 10.3%; 
[baclofen] vs [baclofen + CGP] p<0.05, [baclofen] vs [H22@S$129$ZLWK7XNH\¶V
post-test). 
In addition to increasing the threshold for burst-firing, baclofen application also induced 
hyperpolarization of RTN neurons (Figure 2a), consistent with the activation of a GABAB 
receptor-mediated leak potassium conductance (Ulrich and Huguenard, 1996). Further, we noted 
a corresponding significant decrease in input resistance in response to baclofen (Figure 2b). In 
order to assess the effect of baclofen on burst-firing without the compounding effects of 
hyperpolarization, constant depolarizing current was injecteGWR³PDQXDOO\´UHWXUQWKHUHVWLQJ
membrane potential of RTN neurons to pre-baclofen levels. Under these conditions, baclofen 
still increased the current threshold required for burst-firing (Figures 2c and 2d; control + 
current = 81.3 ± 16.8 pA, baclofen + current = 143.8 ± 32.7 pA; p<0.05). Importantly, although 
the current was still potentiated by baclofen after membrane potential had been returned to the 
pre-baclofen level, the percentage increase in current was significantly lower than when 
membrane potential was not corrected (Figure 2e; baclofen = 169.6 ± 30.7%, baclofen + 
depolarizing current = 83.3 ± 15.6%; P <0.05). This indicates that hyperpolarization alone has a 
significant effect on the suppression of burst-firing following baclofen application.  
Taken together, these data demonstrate for the first time that GABAB receptor activation can 
suppress the activity of burst-firing neurons within the RTN itself. 
 
GABAB receptor activation differentially affects T-type calcium channel isoforms 
Given that T-type calcium channels play a key role in the generation of low threshold burst-
firing (CaV3.2 and CaV3.3 in RTN neurons and CaV3.1 in TR neurons) we next sought to 
establish whether GABAB receptor activation can also modulate T-type calcium currents. 
Performing voltage-clamp in acute brain slices was associated with difficulties in space clamp 
and produced highly variable results, with 3 out of 8 cells showing a significant effect of 
baclofen application (~10%, 25% and 80% inhibition in each affected cell), but with no effect on 
the remaining 5 cells. Notably,  a large fraction of T-type calcium channels are located in 
dendrites and may have been lost in preparing dissociated neurons. As such, we opted to 
undertake a series of exogenous experiments using cloned GABAB1b and GABAB2 receptors co-
transfected with individual CaV3.1, CaV3.2 or CaV3.3 T-type isoforms. 
In order to confirm GABAB receptor expression, Western blotting was performed on lysates 
from HEK 293 cells stably expressing the CaV3.2 channel and co-transfected with GABAB1B 
and GABAB2 receptors (Figure 3a). Further, to validate GABAB receptor functional activity 
GABAB1B and GABAB2 receptors were co-transfected with Kir3.2 in HEK293 cells. 
Application of baclofen resulted in potentiation of the Kir3.2 current in cells expressing GABAB 
receptors but not those expressing Kir3.2 alone (Figure 3c-e).  
Cells co-expressing GABAB receptors with the CaV3.2 T-type channel resulted in a number of 
altered biophysical properties following baclofen application. An increase in CaV3.2 current 
density (normalized to pre-baclofen peak current density values to remove variability in current 
density magnitude between cells) was observed at test potentials between -65 and -45 mV with a 
decrease in current density at more depolarized test potentials (Figure 4a). These effects likely 
occur as a result of a hyperpolarizing shift in the voltage-dependence of activation (Figure 4b 
and 4c; V50: control = -38.9 ± 0.9 mV, baclofen = -45.1 ± 1.1 mV; p<0.005) shifting the current 
density voltage-relationship to the left (Figure 4a). The voltage-dependence of inactivation was 
also shifted towards more hyperpolarized potentials (Figure 4b and 4d; V50: control = -38.9 ± 
0.9 mV, baclofen = -45.1 ± 1.1 mV; p<0.005). No significant effects were observed in the rates 
of activation or inactivation of CaV3.2 currents following GABAB receptor activation (Figure 4e 
and 4f). 
Distinct from the CaV3.2 isoform, in HEK293 cells co-expressing GABAB receptors with the 
CaV3.3 T-subtype there was no significant effect of baclofen on current density (Figure 5a). 
There was also no significant effect observed in the voltage-dependence of activation (Figure 5b 
and 5c). There was a significant shift in the voltage-dependence of inactivation following 
GABAB receptor activation (Figure 5b and 5d; V50: control = -70.9 ± 1.2 mV, baclofen = -75.3 
± 0.8 mV; p<0.05) (Figure 5b). A near significant increase was also observed in the slope factor 
potential following baclofen application (k: control = 5.86 ± 0.37, baclofen = 6.22 ± 0.27 mV; 
p=0.07). Of note, the activation kinetics of CaV3.3 were faster following baclofen application, 
with the Wact displaying a significantly reduced magnitude between -40 and -5 mV (Figure 5e) 
and without any effect observed on inactivation kinetics (Figure 5f)
 
Although the CaV3.1 T-type is not expressed in RTN cells, for completeness concerning the 
specificity of GABAB receptor-mediated modulation we also examined HEK 293 cells co-
expressing GABAB receptor subunits with the CaV3.1.  However, baclofen had little effect on 
any of the biophysical parameters examined.  
 
Discussion 
GABA release within the RTN is believed to induce de-synchronization of thalamic spindle-like 
activity by preventing RTN neurons from burst-firing on each depolarization of an oscillation 
(Sohal and Huguenard, 2003). It is possible that desynchronization of the RTN contributes 
towards termination of both spindle oscillations and seizure activity within the thalamus and 
thalamocortical network, respectively. While the mechanism by which GABA receptors induce 
de-synchronization is not fully understood, it has been shown that selective GABAB receptor 
activation induces the activation of a leak potassium conductance in RTN neurons (Ulrich and 
Huguenard, 1996) and that could be hypothesized to generate hyperpolarization. In the present 
study we examined the activity response of RTN neurons to GABAB receptor activation, 
confirming the induction of hyperpolarization (Ulrich and Huguenard, 1996) and further that it 
occurs concurrently with a decrease in input resistance. Importantly, the amount of depolarizing 
current required to initiate burst-firing was decreased by GABAB receptor activation, even when 
the neuronal resting membrane potential was depolarized to control levels by constant current 
injection. This indicates that GABAB receptor-mediated membrane hyperpolarization alone is 
not sufficient to explain its effects on suppressing RTN burst-firing. Our data suggest that the 
underlying mechanism for suppressed burst-firing via GABAB receptors is the likely result of a 
shunt in excitability due to decreased input resistance. One possible candidate for the cause of 
this drop in input resistance, as well as the hyperpolarization of the membrane potential, is the 
activation of G protein-coupled Inwardly Rectifying Potassium Channels (GIRKS) (Misgeld et 
al., 1995). GIRKs are well-established effectors of GABAB receptors via direct activation by *ȕȖ
subunits causing membrane hyperpolarization by increasing potassium efflux (Reuveny et al., 
1994; Dascal, 1997). A second possible candidate is activation of Two-Pore-Domain Potassium 
(K2P) currents, which have been described in thalamic relay neurons but are yet to be described 
in RTN neurons (Meuth et al., 2006; Musset et al., 2006; Bista et al., 2012). The K2P isoform, 
TREK-1 is potentiated by mGlu4 receptor activation via Gi/Go-mediated inhibition of PKA 
phosphorylation and, as such it is possible that GABAB receptors may also enhance potassium 
conductance through this channel (Cain et al., 2008). It should also be considered that a neuronal 
milieu may be absent in HEK cells, necessary for modulation of CaV3.2 and CaV3.3 channels by 
GABAB either directly by G proteins or via a secondary effector.  
A significant hyperpolarizing shift in the V50 of activation was observed for the CaV3.2 T-type 
channel, resulting in increased current density at hyperpolarized membrane potentials and 
decreased current density at more depolarized membrane potentials. The increased current 
density at hyperpolarized potentials would be predicted to increase the LTCP magnitude, while 
the decreased current density at depolarized potentials may increase calcium conductance during 
action potentials (Kozlov et al., 1999; Chemin et al., 2002; Cain and Snutch, 2010). Neither of 
these effects would be expected to contribute to the suppression of burst-firing observed with 
baclofen application. However, the noted hyperpolarizing shift in the V50 of steady-state 
inactivation would result in a significant reduction in the channel availability between -60 mV 
and -70 mV wherein T-type calcium channels critically contribute towards generating burst-
firing. Parenthetically, we note that considering liquid junction potential correction this would 
equate reduced channel availability between -67.8 mV and -77.8mV; well within the realms of 
LTCP generation. As such, it is feasible that CaV3.2 T-type channel modulation contributes to 
the suppressed burst-firing observed with GABAB receptor activation.  
The CaV3.3 T-type isoform displayed a distinct set of modulatory characteristics in response to 
baclofen application. In one aspect similar to CaV3.2 channels, GABAB receptor activation 
induced a hyperpolarizing shift in the V50 of CaV3.3 steady-state inactivation, resulting in a 
reduction in channel availability at membrane potentials between -70 mV and -80 mV (with 
liquid junction potential correction this would equate to between -77.8 mV and -87.8 mV). 
Distinct from that for CaV3.2 channels, GABAB receptor activation also increased the tau 
activation kinetics of CaV3.3.  This modulatory effect would be expected to increase the rate of 
depolarization during LCTPs and therefore enhance burst-firing. 
Little effect of GABAB receptor activation was observed on the CaV3.1 T-type channel isoform. 
This supports a previous study which demonstrated that baclofen (50 µM) does not affect the 
CaV3.1 T-type current expressed in dorsolateral lateral geniculate thalamocortical neurons 
(Guyon and Leresche, 1995). Also, since CaV3.1 channels are not expressed in the RTN (Talley 
et al., 1999; Joksovic et al., 2006; Astori et al., 2011), the lack of effect of GABAB receptor 
activation on CaV3.1 channels would not be expected to contribute to the observed effect of 
baclofen on burst-firing in the RTN. 
The link between burst-firing, T-type calcium channels and synchronization has been extensively 
studied. Since burst-firing generally increases synchrony in neuronal networks, the de-
synchronizing effect of intra-RTN GABAB-mediated signaling is predicted to result in an 
attenuation of burst-firing (Ulrich and Huguenard, 1996; Sohal and Huguenard, 2003). Our 
results support the notion that GABAB receptor activation suppresses the ability of RTN neurons 
to burst-fire, which in turn may prevent incoming oscillatory volleys from maintaining RTN 
firing in a time-locked manner. This may have important consequences in thalamocortical 
system-mediated seizure generation, wherein a build-up of GABAB-mediated signaling 
throughout the duration of a seizure may lead to de-synchronous activity and seizure termination.  
 
Methods 
Acute brain slice preparation 
P14-P22 Wistar rats (male and female; bred by the Zoology Department and Animal Resource 
Unit at The University of British Columbia, Canada) were used in acute brain slice current clamp 
experiments. Neonatal rats were briefly anaesthetized using halothane, killed by cervical 
dislocation and the brains rapidly removed and placed in ice cold sucrose solution containing in 
mM: 234 sucrose, 24 NaHCO3, 1.25 NaH2PO4, 11 glucose, 2.5 KCl, 0.5 CaCl2, 6 MgCl2, 
bubbled with 95 % O2:5 % CO2. Brain tissue was glued to a cutting chamber, which was then 
filled with ice cold sucrose solution.  Horizontal brain slices containing the whole thalamus 
(neonate ~ 300-ȝP WKLFNZHUHFXW IURPWKH OHYHORI WKHYHQWUDO571DQG LQFXEDWHGIRUD
minimum of one hour at 34oC in a current clamp recording solution containing in mM: 126 
NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2, 10 glucose, 1 kynurenic acid, 0.1 
picrotoxin; bubbled with 95 % O2:5 % CO2.  
 Brain slice electrophysiology 
Slices were transferred to the recording chamber superfused with current clamp recording 
solution and maintained at 33-35oC. RTN neurons were visualized using a DIC microscope 
(Axioskop 2-FS Plus, Carl Zeiss) and infrared camera (IR-1000, DAGE MTI) and visually 
identified by their location, morphology and orientation. All recordings were undertaken using a 
Multiclamp 700B amplifier and pClamp software version 9 (Molecular devices). The 
recording chamber was grounded with an Ag/AgCl pellet. Whole cell current-clamp recordings 
were undertaken using fire polished borosilicate glass pipettes (4-0ȍILOOHGZLWKWKHIROORZLQJ
solution containing in  mM: 120 K-gluconate, 10 HEPES, 1 MgCl2, 1 CaCl2, 11 KCl, 11 EGTA, 
4 MgATP, 0.5 NaGTP , pH adjusted to 7.2 using KOH, osmolarity adjusted to 290 mOsm/kg 
using D-mannitol. The liquid junction potential for current-clamp solutions was calculated as 
+13.3mV and corrected off-line. To evaluate basic neuronal responses to hyperpolarization and 
depolarization, DC current was injected from -110 pA to +200 pA in 10 pA increments for a 
GXUDWLRQRIVHFDWWKHFHOO¶VLQWULQVLFUHVWLQJPHPEUDQHSRWHQWLDO1HXURQVWKDWGLGQRWH[KLELW
burst-firing (as determined by a minimum of 3 action potentials within 100 ms during the current 
step) in response to depolarizing current steps were discarded. Voltage responses under current-
clamp conditions were sampled at 50 kHz and filtered at 10 kHz. Bridge balance was monitored 
during recordings and any neurons displaying briGJH EDODQFH YDOXHV JUHDWHU WKDQ 0ȍ ZHUH
discarded. Capacitance neutralization was performed between 3.8 and 4.2 pF. Data analysis was 
carried out using Clampfit 9 (Axon Instruments Inc.) and software Origin version 8.5 (OriginLab 
Corp., Northampton, MA).  
 
Cell culture 
Human Embryonic Kidney (HEK 293) cell lines stably expressing human T-type calcium 
channels (hCav3.1, hCav3.2 and hCav3.3) were cultured in DMEM media containing 4 mM L-
glutamine, supplemented with 10%  heat inactivated FBS and 10 µl/ml of non-essential amino 
acids (Invitrogen 11140). Cells were grown and maintained at 37oC in a humidified atmosphere 
at 95% air and 5% CO2. Antibiotic selection was used to identify stable transfectants as 
previously described (Belardetti et al., 2009); culture media was supplemented with 25 mg/ml 
zeocin (Invitrogen) for hCav3.1 and hCav3.2 or with 300 mg/ml hygromycin B (Invitrogen) for 
the hCav3.3-expressing cell line. For electrophysiological recordings, cell were plated on 35 mm 
Petri dishes with poly-D-Lysine coated glass coverslips and transiently transfected after 24 hours 
with GABAB receptor subunits, hGABAB1b (in RFP expressing vector # QM512B-1, 
Systembio) and GABAB2 (in GFP expressing vector # CD111B-1, Systembio) using 
Lipofectamine 2000 Reagent (Invitrogen). HEK 293 cells were cotransfected with Kir 3.2 (in 
pcDNA3.1; 0.2 µg/dish), GABAB1b and hGABAB2 (0.25 µg/dish each) and whole cell 
potassium currents were recorded 48 hours after transfection. Stable hCav3.x cell lines were 
cotransfected with hGABAB1b and hGABAB2 (0.25 ± 0.5 µg/dish each) and the DNA-
Lipofectamine complex was removed after three hours incubation and the selection agent 
immediately added to the culture media. T-type calcium currents were recorded 24-48 hours after 
transfection. 
 
HEK 293 cell electrophysiology 
Calcium currents were recorded at room temperature (22-24oC) using the whole-cell voltage-
clamp technique with the following solutions: Internal (mM): 120 Cs-Methanesulphonate, 11 
EGTA, 10 HEPES, 2 MgCl2, 5 MgATP and 0.3 NaGTP (pH 7.2 and osmolality corrected to 310 
mM using D-mannitol); external (mM): 2 CaCl2, 1 MgCl2, 10 HEPES, 40 TEACl, 92 CsCl and 
10 Glucose (pH 7.4). The liquid junction potential was calculated to be 7.8 mV but not corrected 
in data shown. Fire-polished patch pipettes (borosilicate glass) had typical resistances of 3 to 5 
M: when containing internal solution. The recording chamber was grounded with a Ag/AgCl 
pellet. Whole-cell currents were recorded at room temperature using an Axopatch 200B 
amplifier (Axon instruments Inc., Union City, CA). Data were acquired with pClamp software 
package version 9 (Axon Instruments Inc.). Series resistance (Rs) was compensated by 65-75% 
DQGVHDOVZLWK5VYDOXHVKLJKHUWKDQ0ȍRUFHOOVZLWKSHDNFXUUHQWORZHUWKDQS$ZHUH
discarded. Data analysis was carried out using Clampfit 9 (Axon Instruments Inc.) and software 
Origin version 8.5 (OriginLab Corp., Northampton, MA).  
Calcium current-voltage (I-V) relationships were obtained by depolarizing the membrane with 
150 msec pulses from a holding potential of ±110 mV (currents sampled at 10 kHz and filtered at 
2 kHz). Test pulses from -90 to +10 mV were applied at 5 mV steps. Peak amplitude of calcium 
currents was plotted against test pulse potential and I-V curves were fitted using a modified 
Boltzmann equation: I=(Gmax*(Vm-Er))/(1+exp((V50-Vm)/k)), where Gmax is the maximum 
value of membrane conductance, Vm is the test potential, Er is the extrapolated reversal 
potential, V50 is the half-activation potential, and k reflects the voltage sensitivity. Activation 
curves were obtained by calculating conductance from the I-V curves and plotting the 
normalized conductance as a function of the membrane potential.  The data was fitted with the 
Boltzmann equation: G/Gmax = A2 + (A1-A2)/(1 + exp((V50-Vm)/k)), where A1 is minimum 
normalized conductance, A2 is maximum normalized conductance, Vm is the test potential, V50 
is the half-activation potential, and k value the slope of the activation curve (Slope constant). 
Calcium current steady-state inactivation was studied using 90 msec test pulses at -30 mV 
applied after 2 sec conditioning pre-pulses ranging from -120 to -10 mV (currents sampled at 
10k Hz and filtered at 2 kHz). The current magnitude obtained during each test pulse was 
normalized to the maximum at -120 mV and plotted as a function of the pre-pulse potential. The 
data was fitted with the Boltzmann equation: I/Imax = A2 + (A1-A2)/( 1 + exp((Vm-V50)/k)), 
where A1 is minimum normalized current, A2 the maximum normalized current, Vm the test 
potential, V50 the half-inactivation potential, and k the slope of the inactivation curve (Slope 
constant). The time course for activation (Wact ) and inactivation (Winact) were analyzed by fitting 
current recordings obtained from the I-V protocol with an single exponential standard equation: I 
= Ae-t/W, where A is the amplitude of the current, and W is the time constant.  
Inwardly-rectifying potassium currents were recorded using whole cell voltage-clamp with the 
following solutions: Internal (mM): 130 KCl, 20 NaCl, 5 EGTA, 5.5 MgCl2, 10 HEPES, 2.6 K-
ATP, 0.3 Li-GTP (pH correct   ed to 7.4 using KOH and osmolarity corrected to 317 mM using  
D-Mannitol); external (mM): 20 KCl, 140, NaCl, 0.5 CaCl2, 2 MgCl2, 10 HEPES (pH to 7.4 
using NaOH and osmolarity corrected to 310 mM using D-Mannitol). I-V relationships were 
obtained by depolarizing the membrane with 100 msec pulses from a holding potential of ±70 
mV (currents sampled at 10 kHz and filtered at 2 kHz). Test pulses from -100 to +40 mV were 
applied at 10 mV steps. Current response to ramp depolarization was obtained by depolarizing 
the cell from -100 mV to +50 mV over a duration of 180 ms from a holding potential of -100 
mV. 
 
Western blotting 
HEK293 cell extracts were homogenized using Laemmli buffer and liquid nitrogen.  Sample 
lysate concentration was determined using the Pierce 660nm Protein Assay (Fisher # PI22660) 
with the addition of the IDCR reagent (Fisher # PI22663) to compensate for the use of Laemmli 
buffer in the sample preparation. All samples were run on NuPAGE® Novex® 3-8% Tris-
Acetate Midi Gels, from Invitrogen, using NuPAGE Tris-Acetate SDS Running Buffer.  Samples 
for CaVGHWHFWLRQZHUHORDGHGZLWKȝJSHUODQH6DPSOHVIRU*$%$B R1 and GABAB R2 
detection were loaded with ȝJSHUODQH6DPSOHVIRU9LQFXOLQGHWHFWLRQZHUHORDGHGZLWK
ȝJSHUODQH7KHVDPSOHVZHUHEORWWHGRYHUQLJKWDW&UXQQLQJDWP$SHUJHO7KHWUDQVIHU
buffer used contained (in mM) Tris-HCl (40), Sodium Acetate (20), EDTA (2), 20% Methanol 
and 10% SDS (Wang et al., 1989).  Samples were blotted on to Nitrocellulose membrane 
Amersham Hybond ECL 0.45 um (Fisher # 45000929). After transfer, the membranes were 
equilibrated for 10 minutes in TBS + 0.1% Tween-20, then blocked for 1 hour at room 
temperature in TBS-T + 2% non-fat milk powder.  The primary antibodies were diluted in TBS-
T + 2% milk and incubated for 2 hours at room temperature.  The membranes were washed 3 
times for 20 minutes in 2% milk buffer, followed by incubation for one hour at room temperature 
with the secondary antibodies diluted in 2% milk buffer.  After the secondary incubation, the 
membranes were washed three times for 10 minutes in TBS + 0.05% Tween-20.  The ECL 
reagent was then added, and the membranes exposed to Amersham Hyperfilm ECL (Fisher # 
45001505). Antibodies:  Anti-CaV PRXVHPRQRFORQDODQWLERG\DWȝJPO1HXURPDE
#75-095), anti-GABAB 5PRXVHPRQRFORQDODWȝJPO6DQWD&UX]VF-166408 ), anti-
GABAB 5UDEELWSRO\FORQDODWȝJPO6DQWD&UX]VF-28792 ), and anti-vinculin mouse 
monoclonal at 1/10,000 (Sigma #V9131), secondary goat anti-mouse HRP at 1/5000 for GABAB 
R1 and CaV 3.2, and 1/10 000 for vinculin (Pierce # PI32230), and secondary goat anti-Rabbit 
Poly-HRP at 1/5000 (Pierce cat# PI32260). The densitometric results were analyzed using Image 
Studio Lite software (LICOR). 
 
Statistics 
All data plotted as mean ± standard error mean. Data followed a normal distribution and was 
analyzed by Paired Sample t-test or by One-ZD\ $129$ ZLWK 7XNH\¶V SRVW-test where 
appropriate. Significance was considered where p<0.05.  
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 Figure Legends 
 
Figure 1. Baclofen suppresses burst firing in RTN neurons. (a) Representative current clamp 
recordings from neonatal RTN neurons in acute brain slices. Left and middle panels show 
control and baclofen-treated neuronal responses to the varying hyperpolarizing and depolarizing 
current injection protocols shown in right panels. (b) Histogram represents mean data for 
baclofen-treated neurons (n=8) compared to the effects of H2O (n=6) and baclofen perfusion 
with CGP35348 pretreatment (n=9) on burst firing threshold in control (black bars) and treated 
(grey bars) RTN neurons (Paired sample t-test). (c) Histogram represents the percentage change 
in current required to achieve threshold for burst-firing for data in (b) (ANOVA ZLWK7XNH\¶V
post-test). *p<0.05, ***p<0.005. Scale bars represent 20 mV and 200 ms.  
 
Figure 2. Baclofen induces hyperpolarization and decreases input resistance in RTN neurons. 
Histograms representing mean resting membrane potential (a) and input resistance (b) of RTN 
neurons before (black columns) and after (grey columns) baclofen (50 uM) perfusion (n=8). (c) 
Representative current clamp recordings from RTN neurons under control conditions (left panel) 
and in the presence of baclofen with membrane potential corrected to pre-baclofen level with 
constant current injection (right panel). Recordings show response of RTN neurons to same 
current injection protocol (lower panels). (d) Histogram represents mean data from (c) for 
threshold current injection to achieve bursting in control conditions and with membrane-potential 
corrected, baclofen-treated neurons. (e) Histogram represents the percentage change in current 
required to achieve burst-firing for cells where depolarizing current is used to correct membrane 
potential versus cells where membrane potential is not corrected following baclofen-mediated 
hyperpolarization. *p<0.05, ***p<0.005 Paired t-test. Scale bars represent 20 mV and 200 ms. 
 
Figure 3. Expression and validation of GABAB receptors. (a) Western blot of lysates from 
untransfected, CaV3.2 transfected and CaV3.2 plus GABAB1b and GABAB2 transfected HEK 
293 cells, exposed to CaV3.2, GABAB1b, GABAB2 and vinculin antibodies. (b) GFP (bi), RFP 
(bii) and merged GFP/RFP (biii) epi-fluorescence images with a corresponding transmitted light 
image (biv; scale bar = 50 µM) showing expression of GABAB1b (red) and GABAB2 (green) 
reporter genes transfected into HEK 293 cells. (c) Voltage-clamp traces showing response of 
Kir3.2 currents expressed in HEK293 cells in control conditions (left panels) and following 
baclofen (50 µM) application (right panels) in cells expressing Kir3.2 co-transfected with 
GABAB1b and GABAB2 receptors (upper panels) or Kir3.2 alone (lower panels). (d) 
Representative Kir3.2 current in response to a 180 ms ramp depolarization from -100 to +50 mV 
under control conditions (black trace) and following baclofen (50 µM) application (grey trace). 
(e) Histogram represents mean current density data from ramp depolarizations in cells co-
expressing Kir3.2 channels, plus GABAB1B and GABAB2 receptors under control conditions 
(black columns; n=3) and following baclofen (50µM) application (grey column; n=3). Scale bars 
represent 500 pA and 50 ms. **p<0.01. 
 
Figure 4. Mean data for HEK293 cells expressing CaV3.2, GABAB1b and GABAB2 receptors. 
(a) Current density (n=14), (b) current density normalized to peak current density of cell during 
control conditions (n=14), (c) voltage dependence of activation (n=14), stead-state inactivation 
(n=5), (d) tau activation (n=14), (e) tau inactivation (n=14). *p<0.05. 
 
Figure 5. Mean data for HEK293 cells expressing CaV3.3, GABAB1b and GABAB2 receptors. 
(a) Current density (n=7), (b) current density normalized to peak current density of cell during 
control conditions (n=7), (c) voltage dependence of activation (n=7), stead-state inactivation 
(n=3), (d) tau activation (n=7), (e) tau inactivation (n=7). *p<0.05. 
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